GSA Capital Partners’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

GSA Capital Partners’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-61,652	Closed	-$347K	–	1976
2021 Q4	$347K	Buy	61,652 +57,627	+1,432%	+$490K	0.04%	843
2021 Q3	$45K	Sell	4,025 -16,759	-81%	-$211K	﹤0.01%	1350
2021 Q2	$352K	Buy	20,784 +3,098	+18%	+$58.7K	0.04%	842
2021 Q1	$464K	Buy	17,686 +666	+4%	+$30.3K	0.08%	394
2020 Q4	$615K	Buy	17,020 +12,576	+283%	+$455K	0.1%	306
2020 Q3	$157K	Buy	+4,444	New	+$193K	0.03%	1061

Other funds holding EVFM

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's EVFM Position: Q1 2022 in Review

GSA Capital Partners sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2022, closing a stake of 61,652 shares — an estimated $347K sold.

GSA Capital Partners first reported a position in EVFM in Q3 2020 and held it in 6 quarters. The position peaked at $615K in Q4 2020. 68 funds tracked by Wall St. Rank hold EVFM as of Q1 2022.

GSA Capital Partners reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
GSA Capital Partners sold 61,652 Evofem Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $347K.
GSA Capital Partners first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
GSA Capital Partners's Evofem Biosciences, Inc. Common Stock position peaked at $615K in Q4 2020.
68 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.